Evidence map›Paper›PMID 34441288›Full record

ArticleDiagnostics (Basel, Switzerland)2021

Romain-David Seban, Anne Donnadieu, Gabrielle Journo, Francois-Clement Bidard, Capucine Richard, Roman Rouzier, Laurence Champion

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Romain-David SebanDepartment of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France.ORCID 0000-0002-2584-5478
Anne DonnadieuDepartment of Medical Oncology, Institut Curie, PSL Research University, 92210 Saint-Cloud, France.
Gabrielle JournoDepartment of Medical Imaging, Institut Curie, 92210 Saint-Cloud, France.
Francois-Clement BidardDepartment of Medical Oncology, Institut Curie, PSL Research University, 92210 Saint-Cloud, France.ORCID 0000-0001-5932-8949
Capucine RichardDepartment of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France.
Roman RouzierDepartment of Surgery, Institut Curie, PSL Research University, 92210 Saint-Cloud, France.
Laurence ChampionDepartment of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dostarlimab is an immune checkpoint inhibitor (ICI) targeting the Programmed-Death-1 (PD-1) co-receptor, recently approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) as a novel therapy for recurrent or advanced endometrial cancer. We report the case of a 64-year-old woman, experiencing vaginal recurrence with microsatellite instability high/hypermutated of a FIGO stage IA grade 2 endometrial endometrioid adenocarcinoma. She received preoperative chemotherapy with four cycles of carboplatin plus paclitaxel, with stable disease on pelvic magnetic resonance imaging (MRI) and fluorine-18 fluorodeoxyglucose positron emission tomography (

Indexed as

18F-FDG PET/CTdostarlimabendometrial adenocarcinomaimmunotherapymicrosatellite instability high/hypermutatedtumor response

Identifiers

PMID34441288
PMCPMC8391233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.